Dosing For Tumour-Induced Hypercalcaemia (TIH): 4 Mg Dosing And Administration | ZOMETA®
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
Zometa Dosing & Administration: Dosing for TIH


4mg dosing hydration strategies ensuring renal safety references

Treat tumour-induced hypercalcaemia with ZOMETA® 4 mg

  • For patients with TIH, the recommended dose of ZOMETA is 4 mg1
  • ZOMETA 4 mg should be reconstituted and further diluted with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution1
  • ZOMETA should be infused over no less than 15 minutes1
 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.